BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology. 2019;292:376-386. [PMID: 31264946 DOI: 10.1148/radiol.2019182916] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 21.5] [Reference Citation Analysis]
Number Citing Articles
1 Costelloe CM, Amini B, Madewell JE. Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI. Seminars in Ultrasound, CT and MRI 2020;41:170-82. [DOI: 10.1053/j.sult.2019.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
2 Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2021;298:28-35. [PMID: 33170103 DOI: 10.1148/radiol.2020202903] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
3 Shi X, Young CD, Zhou H, Wang X. Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts. Biomolecules 2020;10:E1666. [PMID: 33322749 DOI: 10.3390/biom10121666] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
4 Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 2021;77:517-28. [PMID: 32861792 DOI: 10.1053/j.ajkd.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Starekova J, Bruce RJ, Sadowski EA, Reeder SB. No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid. Radiology 2020;297:556-62. [PMID: 32990511 DOI: 10.1148/radiol.2020200788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Stone RC, Chen V, Burgess J, Pannu S, Tomic-Canic M. Genomics of Human Fibrotic Diseases: Disordered Wound Healing Response. Int J Mol Sci 2020;21:E8590. [PMID: 33202590 DOI: 10.3390/ijms21228590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Schieda N, van der Pol CB, Walker D, Tsampalieros AK, Maralani PJ, Woo S, Davenport MS. Adverse Events to the Gadolinium-based Contrast Agent Gadoxetic Acid: Systematic Review and Meta-Analysis. Radiology 2020;297:565-72. [DOI: 10.1148/radiol.2020200073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
8 Anderson MA, Harrington SG, Kozak BM, Gee MS. Strategies to Reduce the Use of Gadolinium-Based Contrast Agents for Abdominal MRI in Children. American Journal of Roentgenology 2020;214:1054-64. [DOI: 10.2214/ajr.19.22232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
9 Hysi E, Yuen DA. Imaging of renal fibrosis. Curr Opin Nephrol Hypertens 2020;29:599-607. [PMID: 33009130 DOI: 10.1097/MNH.0000000000000650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ponrartana S, Moore MM, Chan SS, Victoria T, Dillman JR, Chavhan GB. Safety issues related to intravenous contrast agent use in magnetic resonance imaging. Pediatr Radiol 2021;51:736-47. [PMID: 33871726 DOI: 10.1007/s00247-020-04896-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Perry HL, Botnar RM, Wilton-ely JDET. Gold nanomaterials functionalised with gadolinium chelates and their application in multimodal imaging and therapy. Chem Commun 2020;56:4037-46. [DOI: 10.1039/d0cc00196a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
12 Alabousi M, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis: Radiology In Training. Radiology 2021;300:279-84. [PMID: 34060939 DOI: 10.1148/radiol.2021210044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lancelot E, Raynaud J, Desché P. Current and Future MR Contrast Agents: Seeking a Better Chemical Stability and Relaxivity for Optimal Safety and Efficacy. Invest Radiol 2020;55:578-88. [DOI: 10.1097/rli.0000000000000684] [Cited by in Crossref: 10] [Article Influence: 10.0] [Reference Citation Analysis]
14 Davenport MS. Virtual Elimination of Nephrogenic Systemic Fibrosis: A Medical Success Story with a Small Asterisk. Radiology 2019;292:387-9. [DOI: 10.1148/radiol.2019191158] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Choi Y, Jang J, Kim J, Nam Y, Shin NY, Ahn KJ, Jeon SS, Kim BS. MRI and Quantitative Magnetic Susceptibility Maps of the Brain after Serial Administration of Gadobutrol: A Longitudinal Follow-up Study. Radiology 2020;297:143-50. [PMID: 32692298 DOI: 10.1148/radiol.2020192579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
16 Malikova H. Nephrogenic systemic fibrosis: the end of the story? Quant Imaging Med Surg 2019;9:1470-4. [PMID: 31559176 DOI: 10.21037/qims.2019.07.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Davenport MS, Shankar PR. Risk of Nephrogenic Systemic Fibrosis from Gadoxetic Acid in Patients with Severe Kidney Disease. Radiology 2020;297:563-4. [DOI: 10.1148/radiol.2020203644] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lum M, Tsiouris AJ. MRI safety considerations during pregnancy. Clin Imaging 2020;62:69-75. [PMID: 32109683 DOI: 10.1016/j.clinimag.2020.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
19 Shankar PR, Davenport MS. Risk of Nephrogenic Systemic Fibrosis in Stage 4 and 5 Chronic Kidney Disease Following Group II Gadolinium-based Contrast Agent Administration: Subanalysis by Chronic Kidney Disease Stage. Radiology 2020;297:447-8. [DOI: 10.1148/radiol.2020201492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
21 Noda SM, Oztek MA, Stanescu AL, Maloney E, Shaw DWW, Iyer RS. Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families. Pediatr Radiol 2021. [PMID: 33978802 DOI: 10.1007/s00247-021-04973-5] [Reference Citation Analysis]
22 Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Med 2021;3:142-50. [PMID: 33604544 DOI: 10.1016/j.xkme.2020.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
23 Sardanelli F, Cozzi A, Trimboli RM, Schiaffino S. Gadolinium Retention and Breast MRI Screening: More Harm Than Good? American Journal of Roentgenology 2020;214:324-7. [DOI: 10.2214/ajr.19.21988] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 13.0] [Reference Citation Analysis]
24 Lange S, Mędrzycka-Dąbrowska W, Zorena K, Dąbrowski S, Ślęzak D, Malecka-Dubiela A, Rutkowski P. Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review. Int J Environ Res Public Health 2021;18:3000. [PMID: 33804005 DOI: 10.3390/ijerph18063000] [Reference Citation Analysis]
25 Suh J, Kim JH, Kim SY, Cho N, Kim DH, Kim R, Kim ES, Jang MJ, Ha SM, Lee SH, Chang JM, Moon WK. Noncontrast-Enhanced MR-Based Conductivity Imaging for Breast Cancer Detection and Lesion Differentiation. J Magn Reson Imaging 2021;54:631-45. [PMID: 33894088 DOI: 10.1002/jmri.27655] [Reference Citation Analysis]
26 Prince MR. A Breakthrough in Gadolinum-based Contrast Agent Hypersensitivity Reactions. Radiology 2020;296:322-3. [DOI: 10.1148/radiol.2020201644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]